Evidence map›Paper›PMID 42058204›Full record

ArticleFrontiers in immunology2026

LGMN

Weixin Zhang, Dapeng Chen, Jinming Li, Tianze Wang, Chengyu Jia, Yi Bai, Yamin Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weixin Zhang *First Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Dapeng Chen *First Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Jinming LiFirst Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Tianze WangSchool of Medicine, Nankai University, Tianjin, China.
Chengyu JiaFirst Central Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Yi BaiDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China.
Yamin ZhangDepartment of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tumor-associated macrophages (TAMs) are known to facilitate cancer progression. However, the diversity of TAM subsets and their distinct roles in GC remain poorly understood. This study aimed to evaluate the impact of legumain (LGMN) Methods: We used single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (bulk RNA-seq) analyses from public databases (GEO and TCGA) to systematically evaluate the clinical prognostic significance of LGMN and to characterize the remodeling of its associated signaling pathways. To investigate the role of LGMN in mouse GC (TAMs), we generated macrophage-specific LGMN conditional knockout mice, LGMN Results: We found that LGMN Conclusions: LGMN

Indexed as

Cysteine EndopeptidasesMacrophagesStomach NeoplasmsTumor-Associated MacrophagesTumor MicroenvironmentAnimalsAsparaginyl EndopeptidaseCell Line, TumorFemaleHumansMiceMice, KnockoutNeovascularization, PathologicAsparaginyl EndopeptidaseCysteine Endopeptidasesangiogenesisgastric cancerimmunosuppressionlegumainmacrophage

Identifiers

PMID42058204
PMCPMC13120899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.